Laura Bessen
Direktor/Vorstandsmitglied bei C4 THERAPEUTICS, INC.
Vermögen: - $ am 31.05.2024
Profil
Laura Bessen is an Independent Director at C4 Therapeutics, Inc. and Artiva Biotherapeutics, Inc. She previously worked as the Vice President & Head-US Medical at Bristol Myers Squibb Co. Dr. Bessen holds an undergraduate degree from the State University of New York at Binghamton and a doctorate degree from New York University School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
C4 THERAPEUTICS, INC.
-.--% | 23.04.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Laura Bessen
| Unternehmen | Position | Beginn |
|---|---|---|
| C4 THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 29.07.2022 |
Artiva Biotherapeutics, Inc.
 Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | Direktor/Vorstandsmitglied | 03.03.2022 |
Ehemalige bekannte Positionen von Laura Bessen
| Unternehmen | Position | Ende |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2016 |
Ausbildung von Laura Bessen
| New York University School of Medicine | Doctorate Degree |
| State University of New York at Binghamton | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| C4 THERAPEUTICS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | Health Technology |
